MAXAIR
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Nov 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXAIR is a metered-dose aerosol inhaler approved in 1992 for respiratory indications. The specific mechanism of action and therapeutic class are not disclosed in available data. This is a small-molecule inhalation product with a long commercial history.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential workforce realignment and transition planning within the brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MAXAIR currently shows zero linked job openings, reflecting its mature and declining stage. Career opportunities on this product are limited; professionals should consider roles in pipeline products, LOE transition planning, or specialty pharmaceutical roles at Bausch + Lomb.
Brand ManagerCommercial Operations
Worked on MAXAIR at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.